Small LDL Particles
Lipids marker
LDL Small
Small LDL Particles
The concentration of small, dense LDL particles measured by advanced lipoprotein testing (NMR or ion mobility). Small dense LDL is the most atherogenic LDL subclass: these particles penetrate the arterial wall more readily, are more prone to oxidation, and persist longer in circulation.
PED Notes
Small dense LDL (sdLDL) is the LDL subfraction most strongly tied to cardiovascular risk, over and above total LDL cholesterol. This is a genuine and important harm-reduction marker for enhanced athletes: AAS suppress HDL and shift LDL toward the small, dense phenotype, and oral 17-alpha-alkylated compounds (stanozolol, oxandrolone) and trenbolone are especially bad for it. Insulin resistance from GH/insulin use and high triglycerides push LDL even smaller. So a lean, apparently healthy bodybuilder can show a relatively modest LDL-C while carrying a highly atherogenic small dense LDL burden, which is exactly the discordance advanced lipoprotein testing exists to catch. Read it with ApoB, LDL-P, triglycerides, and HDL. Reference ranges for subfractions are strongly method and lab dependent (NMR LipoProfile, ion mobility, Boston Heart differ), so trend against the same assay rather than a universal cut-off.
When high
When small dense LDL is elevated (highly atherogenic):
Diet and supplements:
- Reduce refined carbohydrate and sugar (the main dietary driver of small dense LDL) and lower triglycerides
- Omega-3 (EPA/DHA) -- 2-4g/day; shifts LDL toward larger, less atherogenic particles
- Citrus Bergamot -- 500mg 2x/day
- Regular aerobic exercise, which is among the most effective interventions for shifting LDL toward larger particles
Lifestyle/cycle:
- If on oral AAS or trenbolone with a worsening small dense LDL burden, strongly consider dropping the oral/harsh compound or shortening the cycle
Pharmacological options:
- Statins (rosuvastatin 5-20mg/day) primarily cut particle number and ApoB, which lowers overall risk even if size changes less
- Fenofibrate 145-200mg/day (PPAR-alpha agonist) lowers triglycerides and shifts LDL toward larger particles; useful when triglycerides are high
- Ezetimibe 10mg/day, bempedoic acid 180mg/day, or PCSK9 inhibitors as add-ons for ApoB-driven risk
- GLP-1 agonists (semaglutide, tirzepatide) improve the profile indirectly via insulin sensitivity and triglyceride reduction, useful for GH/MK-677 users
- All prescription items require physician oversight and baseline liver/CK monitoring. See the LDL, LDL Size, and ApoB markers for full protocols.
History Chart
Reading History
Frequently Asked Questions
Reference Ranges
Standard Range
VitalMetrics Range